Syntal Capital Partners’s Edwards Lifesciences EW Stock Holding History

Syntal Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8,400	Closed	-$407K	–	152
2018 Q2	$407K	Hold	8,400	–	–	0.15%	93
2018 Q1	$390K	Hold	8,400	–	–	0.14%	98
2017 Q4	$315K	Buy	+8,400	New	+$308K	0.1%	129
2016 Q4	–	Sell	-8,307	Closed	-$333K	–	115
2016 Q3	$333K	Buy	+8,307	New	+$313K	0.2%	35
2015 Q3	–	Sell	-9,012	Closed	-$213K	–	143
2015 Q2	$213K	Buy	+9,012	New	+$203K	0.21%	53

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Syntal Capital Partners's EW Position: Q3 2018 in Review

Syntal Capital Partners sold out of Edwards Lifesciences (EW) in Q3 2018, closing a stake of 8,400 shares — an estimated $407K sold.

Syntal Capital Partners first reported a position in EW in Q2 2015 and held it in 5 quarters. The position peaked at $407K in Q2 2018. 852 funds tracked by Wall St. Rank hold EW as of Q3 2018.

Syntal Capital Partners reported no remaining Edwards Lifesciences position as of Q3 2018 after selling out during the quarter.
Syntal Capital Partners sold 8,400 Edwards Lifesciences shares in Q3 2018, an estimated $407K.
Syntal Capital Partners first reported a position in Edwards Lifesciences in Q2 2015 and held it in 5 quarters.
Syntal Capital Partners's Edwards Lifesciences position peaked at $407K in Q2 2018.
852 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2018.

Based on Syntal Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.